Clinical Trial

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-01-24; most recent amendment 2025-05-30.
Status change: Recruiting → Active, Not Recruiting 2024-02-20
Trial Details
NCT Number NCT03817320
Lead Sponsor Therapeutic Advances in Childhood Leukemia Consortium
Collaborators: Takeda, Children's Hospital Los Angeles
Conditions ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Enrollment 24 participants
Start Date 2019-02-12
Primary Completion 2023-12-03 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-17